ArticleMolecular imaging and biology2023
Diagnostic and Dosimetry Features of [
Article in Molecular imaging and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- [Molecular imaging and biology · 2026Article
- U-Net-based transfer learning for automated tumour segmentation enabling fully automated [Brain informatics · 2026Article
- Preclinical Theranostic Profiling of [Molecules (Basel, Switzerland) · 2025Article
- From Seeing to Healing: The Clinical Potential of Radiotracers in Pediatric Neuro-Oncology.Cancers · 2025Review
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- Article
- Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review.Journal of cancer research and clinical oncology · 2024Review
- The Impact of PET/CT on Paediatric Oncology.Diagnostics (Basel, Switzerland) · 2023Review
- Editorial:Frontiers in medicine · 2023Article
- Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
Abstract
purpose of the reportPaediatric diffuse high-grade gliomas (PDHGG) are rare central nervous system neoplasms lacking effective therapeutic options. Molecular imaging of tumour metabolism might identify novel diagnostic/therapeutic targets. In this study, we evaluated the distribution and the dosimetry aspects of [ MATERIAL AND
methodsPaediatric patients with PDHGG were prospectively recruited. [
resultsTen patients were enrolled (median age 9, range 6-16 years, 6 females). Diagnoses were diffuse midline gliomas (n = 8, 5 of which with H3K27 alterations) and diffuse hemispheric gliomas (n = 2). Six patients had visible tracer uptake (SUV: 1.0 ± 0.6 TBR: 5 ± 3.1). [
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.